February 24, 2026
UBT251 strengthens obesity landscape while CagriSema misses the mark
Novo Nordisk’s mid‑stage “triple G” obesity candidate UBT251 showed up to ~19.7 % mean weight loss in a Chinese phase 2…
Pharmaceuticals, Biotechnology and Life Sciences
Novo Nordisk’s mid‑stage “triple G” obesity candidate UBT251 showed up to ~19.7 % mean weight loss in a Chinese phase 2…
Novo Nordisk reports up to 19.7% mean weight loss in Phase 2 trial of triple agonist UBT251, expanding its next-generation obesity pipeline.
GREENSBORO, N.C., Feb. 18, 2026 (GLOBE NEWSWIRE) — Precise Bio, Inc. (“Precise Bio” or the “Company”), a clinical-stage regenerative medicine…
EMERYVILLE, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) — XOMA Royalty Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today members…
MIRAMAR, Fla., Feb. 17, 2026 (GLOBE NEWSWIRE) — HCW Biologics Inc. (the “Company”), (NASDAQ: HCWB), a U.S.-based clinical-stage biopharmaceutical company…
Management will participate in three upcoming investor healthcare conferencesSALT LAKE CITY, Feb. 16, 2026 (GLOBE NEWSWIRE) — Myriad Genetics, Inc.…
Mechelen, Belgium; February 16, 2026, 22:01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) received a transparency notification…
Army medic–turned–PharmD launches BetterLungs™ after losing relatives to smoking-related respiratory illnessSAN ANTONIO, Feb. 16, 2026 (GLOBE NEWSWIRE) — Betterbrand, a…
SAN DIEGO, CA, Feb. 16, 2026 (GLOBE NEWSWIRE) — Sapu Bioscience today announced advancements in its global IP portfolio supporting…
MELVILLE, N.Y., Feb. 13, 2026 (GLOBE NEWSWIRE) — BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a late stage…